ABSTRACT
HTLV-1 is a retrovirus virus that infects CD4+ T cells. Most people with HTLV-1 infection remain asymptomatic but some may develop conditions such as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) or adult T-cell leukemia/lymphoma. HAM/TSP is characterized by progressive spasticity and weakness of the lower extremities, as well as loss of bladder control and sensory disturbances. The risk of developing HAM/TSP is associated with the duration of infection and the proviral load. There is currently no cure for the disease but medications can help manage symptoms and slow the progression of the disease. This is the case of a 66-year-old female who presented with nonspecific symptoms of weakness and spasticity in a hospital in Connecticut and was subsequently diagnosed with HAM/TSP. The patient's diagnosis highlights the importance of considering diseases previously confined to specific endemic regions in a globalized world where increased emigration and population mixing can occur. Early identification and management of such cases is essential for optimizing patient outcomes and quality of life.
Subject(s)
HTLV-I Infections , Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic , Adult , Female , Humans , Aged , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/therapy , Paraparesis, Tropical Spastic/complications , Quality of Life , HTLV-I Infections/complications , HTLV-I Infections/diagnosis , HTLV-I Infections/therapy , Risk FactorsABSTRACT
INTRODUCTION: Nearly 2-3% of those 10 to 20 million individuals infected with the Human T-cell lymphotropic virus type-1 (HTLV-1); are predisposed to developing HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). It is a neuro-inflammatory disease; differentiated from multiple sclerosis based on the presence of typical neurologic symptoms, confirmation of HTLV-1 infection, and other molecular biomarkers. AREAS COVERED: A brief review of the epidemiology, host immune responses, and molecular pathogenesis of HAM/TSP is followed by detailed discussions about the host-related risk factors for developing HAM/TSP and success/failure stories of the attempted management strategies. EXPERT OPINION: Currently, there is no effective treatment for HAM/TSP. Anti-retroviral therapy, peculiar cytokines (IFN-α), some anti-oxidants, and allograft bone marrow transplantation have been used for treating these patients with limited success. Under current conditions, asymptomatic carriers should be examined periodically by a neurologist for early signs of spinal cord injury. Then it is crucial to determine the progress rate to adapt the best management plan for each patient. Corticosteroid therapy is most beneficial in those with acute myelitis. However, slow-progressing patients are best managed using a combination of symptomatic and physical therapy. Additionally, preventive measures should be taken to decrease further spread of HTLV-1 infection.
Subject(s)
HTLV-I Infections , Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic , Humans , Paraparesis, Tropical Spastic/therapy , Paraparesis, Tropical Spastic/diagnosis , HTLV-I Infections/complications , HTLV-I Infections/therapy , HTLV-I Infections/epidemiology , Cytokines , T-LymphocytesABSTRACT
It is not enough to just create medical practice guidelines; they are also required to be implemented into practice. Therefore, we surveyed specialists to determine the extent of the dissemination of the "HAM Practice Guidelines 2019," to quantify gaps, identify challenges, and understand needs in daily practice. The survey also revealed that the 25% of the specialists were unaware of the tests required for confirming human T-cell leukemia virus type I (HTLV-1) infection. Additionally, they had insufficient knowledge of the HTLV-1 infection. About 90.7% of the specialists agreed with the policy of determining treatment intensity based on disease activity. However, the implementation rate of cerebrospinal fluid marker measurement, which is useful for this assessment, was as low as 27%. Hence, it is important to use the findings of this study to further promote awareness about this issue.
Subject(s)
Human T-lymphotropic virus 1 , Leukemia, T-Cell , Paraparesis, Tropical Spastic , Humans , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/therapyABSTRACT
INTRODUCTION: Individuals with human T-cell lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) experience sensorimotor alterations, which can affect functional performance. Virtual reality (VR) videogaming is a therapeutic option, though there is scarce evidence for its use in this population. We aimed to investigate the therapeutic effects of a VR video game on functional mobility, balance, and gait speed in individuals with HAM/TSP. METHODS: We conducted a blinded, crossover clinical trial comprising 29 individuals with HAM/TSP and randomized them into two groups: (1) early therapy: rehabilitative protocol started immediately after the initial evaluation and (2) late therapy: rehabilitative protocol started 10 weeks later. We assessed all participants for balance using the Berg Balance Scale (BBS) scores, functional mobility using the Timed Up and Go (TUG) test, and gait speed using video camera and CvMob software. Differences were considered significant if p<0.05. RESULTS: The early therapy group individuals presented with higher BBS scores (p=0.415), less TUG times (p=0.290), and greater gait speed (p=0.296) than the late therapy group individuals. CONCLUSIONS: VR videogaming is a useful option for rehabilitative therapy in individuals with HAM/TSP; it positively affects balance, functional mobility, and gait speed.
Subject(s)
Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic , Video Games , Virtual Reality , Humans , Paraparesis, Tropical Spastic/therapy , Walking SpeedABSTRACT
Abstract INTRODUCTION: Individuals with human T-cell lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) experience sensorimotor alterations, which can affect functional performance. Virtual reality (VR) videogaming is a therapeutic option, though there is scarce evidence for its use in this population. We aimed to investigate the therapeutic effects of a VR video game on functional mobility, balance, and gait speed in individuals with HAM/TSP. METHODS: We conducted a blinded, crossover clinical trial comprising 29 individuals with HAM/TSP and randomized them into two groups: (1) early therapy: rehabilitative protocol started immediately after the initial evaluation and (2) late therapy: rehabilitative protocol started 10 weeks later. We assessed all participants for balance using the Berg Balance Scale (BBS) scores, functional mobility using the Timed Up and Go (TUG) test, and gait speed using video camera and CvMob software. Differences were considered significant if p<0.05. RESULTS: The early therapy group individuals presented with higher BBS scores (p=0.415), less TUG times (p=0.290), and greater gait speed (p=0.296) than the late therapy group individuals. CONCLUSIONS: VR videogaming is a useful option for rehabilitative therapy in individuals with HAM/TSP; it positively affects balance, functional mobility, and gait speed.
Subject(s)
Humans , Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic/therapy , Video Games , Virtual Reality , Walking SpeedABSTRACT
BACKGROUND: HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an infectious chronic-inflammatory disease, which can lead to lower limb motions. METHODS: The study evaluated the effects of serial Pilates exercises on the clinical and immunological profiles of patients with HAM/TSP. Eight patients with ages ranging from 39 to 70 years old (2 males and 6 females), 2 wheelchair users and 6 with compromised gait, were evaluated. The patients were submitted to 20 Pilates sessions for 10 weeks. Data were collected at 3 time points (beginning of the study, after Pilates sessions and after 10 weeks without Pilates) and consisted of evaluations of the pain level, spasticity, motor strength, balance, mobility, functional capacity, quality of life and quantification of IFN-γ, IL-10 and IL-9 cytokines levels. RESULTS: After the Pilates sessions, significant improvements in pain level, static and dynamic balance, trunk control, mobility and quality of life were observed, with simultaneous and significant reductions in the serum levels of the cytokines IFN-γ and IL-10. However, after 10 weeks without Pilates, there were significant changes in terms of increasing pain and regression of mobility, with no changes in strength, spasticity, functional capacity in any of the periods of the study. CONCLUSIONS: The results suggest that Pilates may be a promising auxiliary physical therapy for patients with HAM/TSP.
Subject(s)
Exercise Movement Techniques , Human T-lymphotropic virus 1 , Paraparesis, Tropical Spastic , Adult , Aged , Exercise Therapy , Female , Humans , Interferon-gamma , Male , Middle Aged , Paraparesis, Tropical Spastic/therapy , Pilot Projects , Quality of Life , T-LymphocytesABSTRACT
People with HTLV-1 associated myelopathy or tropical spastic paraparesis (HAM/TSP) have sensorimotor losses and postural instability, resulting in frequent falls. These findings stimulate the use of exercise protocols associated with postural control. This study investigated the effectiveness of a balance training exercise protocol through a virtual game. This is a randomized crossover clinical trial performed in subjects with imbalance disorders (HAM/TSP). To evaluate postural oscillations by baropodometry (total area, anterior, posterior and lateral projection), the Footwork® system was used and by cinemetry (angle of the body, hip and ankle alignment in the lateral view), the CVMob system. In addition, the Brief Pain Inventory and the WHOQoL Bref were used to measure pain intensity and quality of life. Comparison tests of the averages (intra and inter groups) and correlations were applied considering an alpha of 5% and power of 80%. The study was approved by the Ethics Committee of the Catholic University of Salvador and registered in the Clinical Trials database (NCT02877030). The final sample consisted of 26, predominantly female subjects. An increase in the postural oscillations of the control subjects (p < 0.05), a reduction in the occurrence of falls (p = 0.039) and an improvement in the quality of life of the control-test group (p < 0.05) were observed. Virtual game training did not improve the static balance, promoting an increase in postural oscillations. Immediately after the application of the protocol, there was a reduction in fall occurrence and improvement in the quality of life.
Subject(s)
Accidental Falls/prevention & control , Exercise Therapy/methods , Exercise/psychology , Paraparesis, Tropical Spastic/therapy , Quality of Life/psychology , Anthropometry/instrumentation , Anthropometry/methods , Cross-Over Studies , Female , Human T-lymphotropic virus 1/pathogenicity , Humans , Male , Middle Aged , Pain/physiopathology , Pain/psychology , Pain/virology , Pain Management/methods , Pain Measurement/statistics & numerical data , Paraparesis, Tropical Spastic/physiopathology , Paraparesis, Tropical Spastic/psychology , Paraparesis, Tropical Spastic/virology , Postural Balance/physiology , Treatment Outcome , Virtual Reality Exposure Therapy/methodsABSTRACT
We investigate the possible effects of acupuncture on the improvement of neurological problems in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP)disease. Twenty patients with HAM/TSP were studied in this pre and post-test clinical trial. Urinary incontinence, global motor disability, spasticity, and pain severity were evaluated before, one month, and three-month after the intervention. Analyses demonstrated a significant reduction of urinary symptoms one month after acupuncture (P = 0.023). A significant improvement was observed in patients' pain and the spasticity at the upper extremity joints, one and three-month after the intervention (P < 0.05). This study suggests that body acupuncture can be used as a complementary treatment to improve HAM/TSP neurological symptoms.
Subject(s)
Acupuncture Therapy/methods , HTLV-I Infections/therapy , Human T-lymphotropic virus 1/pathogenicity , Muscle Spasticity/therapy , Pain Management/methods , Paraparesis, Tropical Spastic/therapy , Urinary Incontinence/therapy , Adult , Female , HTLV-I Infections/physiopathology , HTLV-I Infections/virology , Human T-lymphotropic virus 1/growth & development , Humans , Male , Middle Aged , Muscle Spasticity/physiopathology , Muscle Spasticity/virology , Pain/physiopathology , Pain/virology , Paraparesis, Tropical Spastic/physiopathology , Paraparesis, Tropical Spastic/virology , Severity of Illness Index , Treatment Outcome , Urinary Incontinence/physiopathology , Urinary Incontinence/virologyABSTRACT
OBJECTIVE: Human T cell lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive, neurological disease. Chronic activation of CD8+ T cells, as evidenced by increased spontaneous lymphoproliferation and HTLV-1-specific cytotoxic T cells, has been demonstrated in HAM/TSP patients. Since IL-2 and IL-15 stimulate memory CD8+ T cell activity, these cytokines have been implicated in the immunopathogenesis of HAM/TSP. In this phase I trial, we evaluated the safety, pharmacokinetics, and ability of Hu-Mikß1, a humanized monoclonal antibody directed toward the IL-2/IL-15 receptor ß-chain (IL-2/IL-15Rß: CD122), to saturate CD122 and regulate abnormal immune responses in patients with HAM/TSP by inhibition of IL-15 action. METHODS: Hu-Mikß1 was administered intravenously at doses of 0.5 mg/kg, 1.0 mg/kg, or 1.5 mg/kg in a total of nine HAM/TSP patients. Five doses of Hu-Mikß1 were administered at 3-week intervals. The clinical response was evaluated using standardized scales. Viral and immunologic outcome measures were examined including HTLV-1 proviral load, T cell phenotypic analysis and spontaneous lymphoproliferation in HAM/TSP patients. RESULTS: There was no significant toxicity associated with Hu-Mikß1 administration in HAM/TSP patients. Saturation of CD122 by Hu-Mikß1 was achieved in five out of nine HAM/TSP patients. Administration of Hu-Mikß1 was associated with inhibition of aberrant CD8+ T cell function including spontaneous lymphoproliferation and degranulation and IFN-γ expression, especially in HAM/TSP patients that achieved CD122 saturation. INTERPRETATION: The treatment with Hu-Mikß1 had a number of immunological effects on HAM/TSP patients although no clinical efficacy was observed. We also did not see any dose-related toxicity.
Subject(s)
Antibodies, Monoclonal/pharmacology , Interleukin-2 Receptor beta Subunit/antagonists & inhibitors , Paraparesis, Tropical Spastic/immunology , Paraparesis, Tropical Spastic/therapy , Administration, Intravenous , Adult , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , CD8-Positive T-Lymphocytes/drug effects , Cytokines/biosynthesis , Female , HTLV-I Infections/immunology , Human T-lymphotropic virus 1/immunology , Humans , Interferon-gamma/metabolism , Interleukin-15 , Interleukin-2 , Interleukin-2 Receptor beta Subunit/metabolism , Lymphocyte Activation , Male , Middle Aged , Nervous System Diseases , T-Lymphocytes, Cytotoxic/immunologyABSTRACT
Human T-cell leukemia virus type-1 (HTLV-1) causes adult T-cell leukemia/lymphoma (ATL), HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and other inflammatory diseases. There is no disease-specific difference in viral strains, and it is unclear how HTLV-1 causes such different diseases manifesting as lymphoproliferation or inflammation. Although some progress has been made in therapies for these diseases, the prognosis for ATL is still dismal and HAM/TSP remains an intractable disease. So far, two regulatory proteins of HTLV-1, Tax and HBZ, have been well studied and shown to have pleiotropic functions implicated in viral pathogenesis. Tax in particular can strongly activate NFκB, which is constitutively activated in HTLV-1-infected cells and considered to contribute to both oncogenesis and inflammation. However, the expression level of Tax is very low in vivo, leading to confusion in understanding its role in viral pathogenesis. A series of studies using IL-2-dependent HTLV-1-infected cells indicated that IL-10, an anti-inflammatory/immune suppressive cytokine, could induce a proliferative phenotype in HTLV-1-infected cells. In addition, type I interferon (IFN) suppresses HTLV-1 expression in a reversible manner. These findings suggest involvement of host innate immunity in the switch between lymphoproliferative and inflammatory diseases as well as the regulation of HTLV-1 expression. Innate immune responses also affect another important host determinant, Tax-specific cytotoxic T lymphocytes (CTLs), which are impaired in ATL patients, while activated in HAM/TSP patients. Activation of Tax-specific CTLs in ATL patients after hematopoietic stem cell transplantation indicates Tax expression and its fluctuation in vivo. A recently developed anti-ATL therapeutic vaccine, consisting of Tax peptide-pulsed dendritic cells, induced Tax-specific CTL responses in ATL patients and exhibited favorable clinical outcomes, unless Tax-defective ATL clones emerged. These findings support the significance of Tax in HTLV-1 pathogenesis, at least in part, and encourage Tax-targeted immunotherapy in ATL. Host innate and acquired immune responses induce host microenvironments that modify HTLV-1-encoded pathogenesis and establish a complicated network for development of diseases in HTLV-1 infection. Both host and viral factors should be taken into consideration in development of therapeutic and prophylactic strategies in HTLV-1 infection.
Subject(s)
Genes, pX , HTLV-I Infections/immunology , Host Microbial Interactions/immunology , Human T-lymphotropic virus 1/pathogenicity , Immunotherapy , Leukemia-Lymphoma, Adult T-Cell/therapy , Animals , HTLV-I Infections/therapy , Humans , Leukemia-Lymphoma, Adult T-Cell/immunology , Paraparesis, Tropical Spastic/immunology , Paraparesis, Tropical Spastic/therapyABSTRACT
We report the case of a 53-year-old-man who developed human T-cell leukemia virus type-1-associated myelopathy (HAM) after ABO-incompatible liver transplantation for alcoholic liver cirrhosis. The living donor was seropositive for human T-cell leukemia virus type-1 (HTLV-1) and the recipient was seronegative for HTLV-1 before transplantation. After transplantation, the recipient developed steroid-resistant acute cellular rejection, which was successfully treated using anti-thymocyte globulin, and he was eventually discharged. He underwent spinal surgery twice after the transplantation for the treatment of cervical spondylosis that had been present for a period of 9 months before the transplantation. The surgery improved his gait impairment temporarily. However, his gait impairment progressed, and magnetic resonance imaging revealed multiple sites of myelopathy. He was diagnosed with HAM 16 months after the transplantation. Pulse steroid therapy (1000mg) was administered over a period of 3 days, and his limb paresis improved. Presently, steroid therapy is being continued, with a plan to eventually taper the dose, and he is being carefully followed up at our institution. Our case suggests that liver transplantation involving an HTLV-1-positive living donor carries the risk of virus transmission and short-term development of HAM after transplantation.
Subject(s)
ABO Blood-Group System , Antibodies, Viral/blood , Blood Group Incompatibility , Human T-lymphotropic virus 1/immunology , Liver Cirrhosis, Alcoholic/surgery , Liver Transplantation/adverse effects , Living Donors , Paraparesis, Tropical Spastic/transmission , Female , Humans , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Liver Cirrhosis, Alcoholic/diagnosis , Male , Middle Aged , Paraparesis, Tropical Spastic/immunology , Paraparesis, Tropical Spastic/therapy , Paraparesis, Tropical Spastic/virology , Risk Assessment , Time Factors , Treatment OutcomeSubject(s)
HTLV-I Infections/epidemiology , HTLV-I Infections/prevention & control , Human T-lymphotropic virus 1/immunology , Antibodies, Viral/blood , Awareness , Female , HTLV-I Infections/complications , HTLV-I Infections/transmission , Humans , Infectious Disease Transmission, Vertical/prevention & control , Japan/epidemiology , Leukemia-Lymphoma, Adult T-Cell/etiology , Leukemia-Lymphoma, Adult T-Cell/therapy , Male , Paraparesis, Tropical Spastic/etiology , Paraparesis, Tropical Spastic/therapy , Pregnancy , Prenatal Diagnosis/methods , Tissue DonorsABSTRACT
Going back to their discovery in the early 1980s, both the Human T-cell Leukemia virus type-1 (HTLV-1) and the Human Immunodeficiency Virus type-1 (HIV-1) greatly fascinated the virology scene, not only because they were the first human retroviruses discovered, but also because they were associated with fatal diseases in the human population. In almost four decades of scientific research, both viruses have had different fates, HTLV-1 being often upstaged by HIV-1. However, although being very close in terms of genome organization, cellular tropism, and viral replication, HIV-1 and HTLV-1 are not completely commutable in terms of treatment, especially because of the opposite fate of the cells they infect: death versus immortalization, respectively. Nowadays, the antiretroviral therapies developed to treat HIV-1 infected individuals and to limit HIV-1 spread among the human population have a poor or no effect on HTLV-1 infected individuals, and thus, do not prevent the development of HTLV-1-associated diseases, which still lack highly efficient treatments. The present review mainly focuses on the course of HTLV-1 infection, from the initial infection of the host to diseases development and associated treatments, but also investigates HIV-1/HTLV-1 co-infection events and their impact on diseases development.
Subject(s)
HTLV-I Infections/therapy , HTLV-I Infections/transmission , Human T-lymphotropic virus 1/physiology , CD4-Positive T-Lymphocytes/virology , Coinfection/therapy , Coinfection/virology , Drug Discovery , HIV Infections/complications , HTLV-I Infections/complications , HTLV-I Infections/virology , Humans , Leukemia-Lymphoma, Adult T-Cell/therapy , Leukemia-Lymphoma, Adult T-Cell/virology , Paraparesis, Tropical Spastic/therapy , Paraparesis, Tropical Spastic/virology , Virus ReplicationABSTRACT
OBJECTIVE: HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) can progress slowly or rapidly even though a set of symptoms such as spastic paraparesis with pathological reflexes and sweating loss of the lower extremities are commonly observed in patients. Although most of the patients are thought to be infected to HTLV-1 from their mothers by breast feeding, symptoms of HAM/TSP typically manifest in patients later in life (50-60years old in age) and also with a higher prevalence of women to men at a ratio of approximately 3:1. Probability of developing HAM/TSP and how fast an individual's disease may progress from the time of diagnosis could be multifactorial. METHODS: We reviewed the records of 150 patients with HAM/TSP admitted to Kagoshima University Hospital between 2002 and 2014. Laboratory data of cerebrospinal fluid and serum and the clinical measurements including age, age of disease onset, progression rate, duration of illness, initial symptoms, Osame's Motor Disability Score were evaluated. Rapid disease progression of the disease was defined by deterioration of motor disability by >3 grades within 2years. RESULTS: Of 150 HAM/TSP patients in our cohort, 114 cases (76%) were females. Patients presenting with rapid disease progression are approximately 15years older at the age of onset than those with a protracted disease course, and have increased number of cell, and elevated levels of protein as well as anti-HTLV-1 antibody titer in the CSF, suggesting a more active inflammatory process. There is no significant difference in the average values of clinical and laboratory parameters between the sexes. Furthermore, there is no apparent correlation between rate of disease progression and gender. CONCLUSIONS: Our results suggest that age and virus mediated inflammation are correlated with disease phenotypes while additional factors such as host or HTLV-1 genetics and gender may influence disease susceptibility.
Subject(s)
Paraparesis, Tropical Spastic/physiopathology , Adolescent , Adult , Age of Onset , Aged , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Child , Disability Evaluation , Disease Progression , Female , Hospitals, University , Humans , Male , Middle Aged , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/therapy , Phenotype , Young AdultABSTRACT
Kidney transplant recipients are at increased risk of developing clinical disease due to uncommon opportunistic viral pathogens. Refractory anemia is classically associated with parvovirus B19 infection. West Nile virus has the propensity to cause fever and neurologic symptoms, while spastic paresis and lymphoma can be triggered by human T cell lymphotrophic virus. In this review article, the epidemiology, clinical manifestations, diagnosis and treatment of less common viruses are discussed in the setting of kidney transplantation.
Subject(s)
Erythema Infectiosum/chemically induced , Graft Rejection/prevention & control , HTLV-I Infections/chemically induced , Immunosuppressive Agents/adverse effects , Kidney Failure, Chronic/surgery , Kidney Transplantation , Leukemia-Lymphoma, Adult T-Cell/chemically induced , West Nile Fever/chemically induced , Antiviral Agents/therapeutic use , Erythema Infectiosum/diagnosis , Erythema Infectiosum/therapy , HTLV-I Infections/diagnosis , HTLV-I Infections/therapy , Humans , Leukemia-Lymphoma, Adult T-Cell/diagnosis , Leukemia-Lymphoma, Adult T-Cell/therapy , Leukemia-Lymphoma, Adult T-Cell/virology , Paraparesis, Tropical Spastic/chemically induced , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/therapy , Paraparesis, Tropical Spastic/virology , Parvoviridae Infections/chemically induced , Parvoviridae Infections/diagnosis , Parvoviridae Infections/therapy , West Nile Fever/diagnosis , West Nile Fever/therapyABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Paraparesis, Tropical Spastic/epidemiology , Paraparesis, Tropical Spastic/immunology , Paraparesis, Tropical Spastic/therapy , Diagnosis, Differential , Oligoclonal Bands/therapeutic use , Chronic Disease/epidemiology , Chronic Disease/prevention & controlSubject(s)
HTLV-I Infections/etiology , Paraparesis, Tropical Spastic , Astrocytes/metabolism , Biomarkers/analysis , Disease Progression , Humans , Paraparesis, Tropical Spastic/complications , Paraparesis, Tropical Spastic/diagnosis , Paraparesis, Tropical Spastic/metabolism , Paraparesis, Tropical Spastic/therapy , PrognosisABSTRACT
Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy (HAM) is a chronic progressive myelopathy that is characterized by spastic paraparesis with bladder dysfunction that is derived from bilateral pyramidal tract involvement and neurogenic bladder, respectively. The primary neuropathological feature of HAM is chronic inflammation in the spinal cord, mainly the lower thoracic cord, which is characterized by perivascular cuffing and parenchymal infiltration of mononuclear cells. Although it is still unclear why only a very small proportion of HTLV-I carriers develop HAM, the key player in the pathogenesis of HAM is the increase of activated HTLV-I-infected cells in the peripheral blood. The exact cellular and molecular events underlying the induction of chronic inflammation in the spinal cord by HTLV-I are still unclear. However, a long-standing bystander mechanism, such as the destruction of surrounding nervous tissue by the interaction between HTLV-I-infected CD4+ T cells and HTLV-I-specific cytotoxic T cells in the spinal cord, with the cooperation of the positive feedback loop of inflammation that is derived from the migrated HTLV-I-infected cells is probably critical in the immunopathogenesis of HAM. In this review, recent advances in several fields toward the elucidation of the pathomechanisms concomitant with the establishment of new therapeutic strategies in HAM will be discussed along with an overview of the clinical features.
Subject(s)
Paraparesis, Tropical Spastic , Spinal Cord Diseases/etiology , Human T-lymphotropic virus 1/genetics , Humans , Immunity, Innate , Paraparesis, Tropical Spastic/epidemiology , Paraparesis, Tropical Spastic/pathology , Paraparesis, Tropical Spastic/therapy , Prognosis , Spinal Cord Diseases/epidemiology , Spinal Cord Diseases/pathology , Spinal Cord Diseases/therapy , T-Lymphocytes/immunologyABSTRACT
BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) can cause chronic spinal cord inflammation, known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Since CD4(+)CCR4(+) T cells are the main HTLV-1 reservoir, we evaluated the defucosylated humanized anti-CCR4 antibody mogamulizumab as a treatment for HAM/TSP. METHODS: We assessed the effects of mogamulizumab on peripheral blood mononuclear cells from 11 patients with HAM/TSP. We also studied how CD8(+) T cells, namely CD8(+) CCR4(+) T cells and cytotoxic T lymphocytes, are involved in HTLV-1 infection and HAM/TSP pathogenesis and how they would be affected by mogamulizumab. RESULTS: Mogamulizumab effectively reduced the HTLV-1 proviral load (56.4% mean reduction at a minimum effective concentration of 0.01 µg/mL), spontaneous proliferation, and production of proinflammatory cytokines, including interferon γ (IFN-γ). Like CD4(+)CCR4(+) T cells, CD8(+)CCR4(+) T cells from patients with HAM/TSP exhibited high proviral loads and spontaneous IFN-γ production, unlike their CCR4(-) counterparts. CD8(+)CCR4(+) T cells from patients with HAM/TSP contained more IFN-γ-expressing cells and fewer interleukin 4-expressing cells than those from healthy donors. Notably, Tax-specific cytotoxic T lymphocytes that may help control the HTLV-1 infection were overwhelmingly CCR4(-). CONCLUSIONS: We determined that CD8(+)CCR4(+) T cells and CD4(+)CCR4(+) T cells are prime therapeutic targets for treating HAM/TSP and propose mogamulizumab as a new treatment.